291 related articles for article (PubMed ID: 15921960)
1. Intratumoral injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells.
Vera M; Razquin N; Prieto J; Melero I; Fortes P; González-Aseguinolaza G
Mol Ther; 2005 Nov; 12(5):950-9. PubMed ID: 15921960
[TBL] [Abstract][Full Text] [Related]
2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
3. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells.
Luo X; Yu Y; Liang A; Xie Y; Liu S; Guo J; Wang W; Qi R; An H; Zhang M; Xu H; Guo Z; Cao X
Cell Mol Immunol; 2004 Jun; 1(3):199-204. PubMed ID: 16219168
[TBL] [Abstract][Full Text] [Related]
6. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity.
Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Miyagi T; Jinushi M; Sakamori R; Kohga K; Uemura A; Ohkawa K; Storkus WJ; Hayashi N
Gene Ther; 2007 Jun; 14(11):863-71. PubMed ID: 17344900
[TBL] [Abstract][Full Text] [Related]
7. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
Ishii S; Hiroishi K; Eguchi J; Hiraide A; Imawari M
Gene Ther; 2006 Jan; 13(1):78-87. PubMed ID: 16107857
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18.
Tanaka F; Hashimoto W; Robbins PD; Lotze MT; Tahara H
Gene Ther; 2002 Nov; 9(21):1480-6. PubMed ID: 12378411
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
Eguchi J; Hiroishi K; Ishii S; Mitamura K
Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
[TBL] [Abstract][Full Text] [Related]
13. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.
Hu J; Yuan X; Belladonna ML; Ong JM; Wachsmann-Hogiu S; Farkas DL; Black KL; Yu JS
Cancer Res; 2006 Sep; 66(17):8887-96. PubMed ID: 16951206
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas.
Melero I; Duarte M; Ruiz J; Sangro B; Galofré J; Mazzolini G; Bustos M; Qian C; Prieto J
Gene Ther; 1999 Oct; 6(10):1779-84. PubMed ID: 10516729
[TBL] [Abstract][Full Text] [Related]
15. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.
Chen Y; Emtage P; Zhu Q; Foley R; Muller W; Hitt M; Gauldie J; Wan Y
Gene Ther; 2001 Feb; 8(4):316-23. PubMed ID: 11313806
[TBL] [Abstract][Full Text] [Related]
16. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096
[TBL] [Abstract][Full Text] [Related]
18. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
[TBL] [Abstract][Full Text] [Related]
19. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
Gambotto A; Tüting T; McVey DL; Kovesdi I; Tahara H; Lotze MT; Robbins PD
Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963
[TBL] [Abstract][Full Text] [Related]
20. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.
Kirk CJ; Hartigan-O'Connor D; Nickoloff BJ; Chamberlain JS; Giedlin M; Aukerman L; Mule JJ
Cancer Res; 2001 Mar; 61(5):2062-70. PubMed ID: 11280767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
